FAQ/Help |
Calendar |
Search |
Today's Posts |
06-11-2010, 05:02 AM | #1 | |||
|
||||
Senior Member
|
One of the greatest challenges facing biomedical sciences in the 21st century is the development of fundamentally better treatments for neurodegenerative diseases... Alzheimer's disease and Parkinson's disease, are the initial focus of the Coalition Against Major Diseases.
http://c-path.org/CAMD.cfm OUR PURPOSE The CAMD's focus is to develop new tools and methods that can be applied during the development of new treatments for these diseases that have remained beyond the reach of drug discovery and continue to result in added costs for treatment, chronic suffering, and the loss of lives. CAMD fosters innovative testing methods that lead to increased efficiency, safety, and speed in developing new therapies... The Coalition will not duplicate efforts already underway in these areas, but will leverage existing data and knowledge, creating consensus on methods which will advance product development, and make these new methods available for public use. OUR GOALS The initial goal of CAMD is to define clinical data standards and establish a pooled database of the control groups of pharmaceutical clinical trials in order to develop quantitative disease progression models for both Alzheimer's and Parkinson's diseases. Coalition members also will work together to incorporate ... biomarkers that have the greatest potential to identify patient populations that are most likely to benefit with the lowest risk of harm from new therapies. Just as importantly, CAMD members will collaborate to gather and submit the evidence necessary for the FDA and EMA to officially designate such tools as "qualified for use" in drug development. These newly qualified tools will be made publicly available for use by scientists and commercial developers. OUR MEMBERS CAMD participants are member organizations that include six patient groups, fifteen biopharmaceutical companies, as well as advisors from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute on Aging (NIA):
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
Reply With Quote |
06-11-2010, 04:21 PM | #2 | ||
|
|||
In Remembrance
|
i'm glad to see this collaboration. hoping that they will multi-task and not ignore patients or out of the box thinking. CAMre, for example was a one issue collaboration - stem cells.
this collaboration has wonderful potential, but we must be vigilante about being grouped together with alzheimers regarding neurotransmitters. look forward to what this group will do and how quickly they will do it. we seem to need the computer databases to survive. paula
__________________
paula "Time is not neutral for those who have pd or for those who will get it." Last edited by paula_w; 06-11-2010 at 04:31 PM. Reason: adding a sentence |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
American Indians for McCain Coalition debuts at GOP convention | Social Chat |